Q BioMed (Q BioMed) Days Payable : 66,688.54 (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Days Payable?

Q BioMed's average Accounts Payable for the three months ended in Feb. 2023 was $2.19 Mil. Q BioMed's Cost of Goods Sold for the three months ended in Feb. 2023 was $0.00 Mil. Hence, Q BioMed's Days Payable for the three months ended in Feb. 2023 was 66,688.54.

The historical rank and industry rank for Q BioMed's Days Payable or its related term are showing as below:

QBIO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Q BioMed's Days Payable increased from Feb. 2022 (1,942.15) to Feb. 2023 (66,688.54). It may suggest that Q BioMed delayed paying its suppliers.

Q BioMed Days Payable Historical Data

The historical data trend for Q BioMed's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Days Payable Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Days Payable

Get a 7-Day Free Trial

769.19

1,527.24

2,165.71

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
Days Payable	Get a 7-Day Free Trial															1,942.15	2,380.74	2,787.27	2,372.50	66,688.54

Competitive Comparison of Q BioMed's Days Payable

For the Biotechnology subindustry, Q BioMed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Days Payable distribution charts can be found below:

* The bar in red indicates where Q BioMed's Days Payable falls into.

Q BioMed Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Q BioMed's Days Payable for the fiscal year that ended in Nov. 2022 is calculated as

	Days Payable (A: Nov. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Nov. 2021 )	+	Accounts Payable (A: Nov. 2022 ))	/	count )	/	Cost of Goods Sold (A: Nov. 2022 )	*	Days in Period
=	( (1.345	+	2.132)	/	2 )	/	0.293	*	365
=	1.7385					/	0.293	*	365
=	2,165.71

Q BioMed's Days Payable for the quarter that ended in Feb. 2023 is calculated as:

	Days Payable (Q: Feb. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Nov. 2022 )	+	Accounts Payable (Q: Feb. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Feb. 2023 )	*	Days in Period
=	( (2.132	+	2.253)	/	2 )	/	0.003	*	365 / 4
=	2.1925					/	0.003	*	365 / 4
=	66,688.54

Q BioMed Days Payable Related Terms

Thank you for viewing the detailed overview of Q BioMed's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1